Gastrointestinal Cancer | Specialty

The gastrointestinal cancer condition center is a comprehensive resource for clinical news and expert insights on gastrointestinal cancer. Read more at OncLive.

Dr Elimova on the Efficacy of Zanidatamab With Chemotherapy in HER2+ Advanced/Metastatic Gastroesophageal Adenocarcinoma

June 14th 2025

Elena Elimova, MD, discusses the efficacy of zanidatamab with chemotherapy in HER2-positive advanced gastroesophageal adenocarcinoma.

FDA Grants Fast Track Designation to CHM CDH17 for Gastroenteropancreatic NETs

June 12th 2025

CHM CDH17 has received fast track designation from the FDA for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target

June 9th 2025

Daneng Li, MD, discusses the IL-27–targeted agent casdozokitug in hepatocellular carcinoma.

Casdozokitug Plus Atezolizumab/Bevacizumab Yields Antitumor Activity in Unresectable, Advanced HCC

June 5th 2025

Daneng Li, MD, discusses the efficacy and safety findings of a casdozokitug-based regimen in unresectable, advanced HCC.

Fruquintinib Plus Chemotherapy and PD-1 Inhibition Is Safe and Active in Treatment-Naive HER2– Gastric/GEJ Adenocarcinoma

June 4th 2025

Fruquintinib plus chemotherapy and a PD-1 inhibitor was safe and effective in patients with untreated HER2-negative advanced gastric/GEJ cancer.

Frontline Disitamab Vedotin Yields Responses in Gastric/GEJ Cancer With Various HER2 Expression Levels

June 2nd 2025

The addition of disitamab vedotin to toripalimab and trastuzumab and/or CAPOX led to favorable response rates in HER2-expressing gastric/GEJ cancer.

EBC-129 Is Active and Safe in Heavily Pretreated mPDAC

June 2nd 2025

EBC-129 monotherapy was active, generated responses, and had a manageable safety profile in heavily pretreated metastatic pancreatic ductal adenocarcinoma.

Preoperative PAXG Extends EFS in Resectable and Borderline Resectable Pancreatic Cancer

June 1st 2025

Neoadjuvant therapy with PAXG chemotherapy prolonged event-free survival vs mFOLFIRINOX in patients with stage I to III pancreatic ductal adenocarcinoma.

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected Esophageal/GEJ Cancer

June 1st 2025

Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.

Addition of TTFields to Gemcitabine/Nab-Paclitaxel Boosts OS in Locally Advanced PDAC

June 1st 2025

TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.

Perioperative Durvalumab Plus FLOT Represents New SOC in Resectable Gastric/GEJ Adenocarcinoma

June 1st 2025

The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.

NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX

June 1st 2025

A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.

First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC

June 1st 2025

A fruquintinib regimen appeared safe and effective when used as a frontline treatment in esophageal squamous cell carcinoma.

Dr Picozzi on the Addition of TTFields to Gemcitabine and Nab-Paclitaxel in Locally Advanced PDAC

May 31st 2025

Vincent Picozzi, MD, discusses the addition of TFields to gemcitabine and nab-paclitaxel in locally advanced pancreatic ductal adenocarcinoma.

T-DXd Represents a New SOC in Second-Line HER2+ Gastric/GEJ Cancer

May 31st 2025

T-DXd demonstrated clinically meaningful antitumor responses as second-line treatment in HER2-positive gastric/GEJ cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025

May 30th 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer

May 30th 2025

China’s NMPA approved zanidatamab for previously treated, unresectable or metastatic, HER2-positive biliary tract cancer.

Neoantigen-Reactive TILs With CISH Knockout Are Safe and Effective in Metastatic GI Tumors

May 29th 2025

CRISPR-Cas9–mediated CISH gene knockout TIL therapy was well tolerated and demonstrated early signals of efficacy in metastatic GI epithelial cancer.

FDA Grants Fast Track Status to EBC-129 for Pancreatic Ductal Adenocarcinoma

May 29th 2025

EBC-129 has been awarded fast track designation from the FDA for patients with pancreatic ductal adenocarcinoma.

FOLFIRINOX Significantly Improves PFS Over Gemcitabine in Locally Advanced Pancreatic Carcinoma

May 28th 2025

NEOPAN data support the superiority of FOLFIRINOX over gemcitabine in locally advanced pancreatic carcinoma.